Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer

Table 2

Univariate and multivariate odds ratios for the risk of ≥10 lbs weight gain 6 months after randomization for each clinical factor.

Clinical factor	Number of men	Number of men who gained ≥10 lbs by EOT	Univariable analysis		Multivariable analysis
			OR (95% CI)	𝑃 value	AOR (95% CI)	𝑃 value
RT	85	2	0.18; (0.04, 0.86)	0.03	0.18; (0.04, 0.89)	0.04
RT + AST	86	10	1 (Ref)	—	1 (Ref)	—
BMI increase per kg/m^2	171	12	1.18; (1.05, 1.33)	0.01	1.15; (1.01, 1.31)	0.04
PSA increase per ng/mL	171	12	0.98; (0.90, 1.06)	0.58	0.97; (0.87, 1.08)	0.57
Age	171	12	0.93; (0.85, 1.02)	0.14	0.95; (0.85, 1.06)	0.38
Gleason score 8 to 10	26	3	2.09; (0.39, 11.15)	0.39	1.17; (0.17, 7.93)	0.87
7	94	6	1.091; (0.26, 4.56)	0.90	0.55; (0.10, 3.06)	0.49
6 or less	51	3	1 (Ref)	—	1 (Ref)	—
T2	88	8	1.98; (0.57, 6.82)	0.28	1.99; (0.49, 7.99)	0.33
T1	83	4	1 (Ref)	—	1 (ref)	—
Mod to Sev cm	41	5	2.44; (0.73, 8.15)	0.15	2.11; (0.54, 8.26)	0.28
No or min cm	130	7	1 (Ref)	—	1 (Ref)	—

RT indicates radiotherapy; ADT: androgen deprivation therapy; BMI: body mass index; PSA: prostate-specific antigen; cm: comorbidity; OR: odds ratio; CI: confidence interval; AOR: adjusted odds ratio; EOT: end of treatment.